Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

HEMLIBRA DIN 02556049

Status: Marketed
Holder: HOFFMANN-LA ROCHE LIMITED
Molecule: EMICIZUMAB

Health Canada record

Active ingredient(s)EMICIZUMAB 12 MG
Dosage formSolution
RouteSubcutaneous
ScheduleSCHEDULE D; PRESCRIPTION
ClassHuman
ATCB02BX06 EMICIZUMAB
Original market date10-Dec-2025
Current status date10-Dec-2025
SourceHealth Canada DPD

Establishment licence of the holder

Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing EMICIZUMAB

DINProductCompanyFormStrengthStatus
02479621HEMLIBRAHOFFMANN-LA ROCHE LIMITEDSolutionEMICIZUMAB 30 MGMarketed
02479648HEMLIBRAHOFFMANN-LA ROCHE LIMITEDSolutionEMICIZUMAB 60 MGMarketed
02479656HEMLIBRAHOFFMANN-LA ROCHE LIMITEDSolutionEMICIZUMAB 105 MGMarketed
02479664HEMLIBRAHOFFMANN-LA ROCHE LIMITEDSolutionEMICIZUMAB 150 MGMarketed
02556057HEMLIBRAHOFFMANN-LA ROCHE LIMITEDSolutionEMICIZUMAB 300 MGMarketed

Notices of Compliance

NOCDateSubmissionReason
349812025-03-06Supplement to a New Drug Submission (SNDS)New fill volume. Change in manufacturing process
Request a quote for HEMLIBRA

How to read a Canadian DIN record